DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199 DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have ...
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report) today. The company’s shares closed yesterday at $6.61. See what stocks are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback